A Track Record of Success
Ten to fifteen years is too long for a person with a life-threatening illness to wait for a new treatment or cure, yet that is the average timeframe for potential new drugs to make it to the marketplace. Identifying the underlying cause of a disease is the first step in the drug discovery process.
In the past decade alone, Institute faculty have:
- Made revolutionary discoveries, based on the convergence of chemistry, physics, engineering and life sciences, for detection and treatment of cancer, infertility, common and rare neurodegenerative diseases, and imaging and manipulation of cell behavior
- Advanced 75 new drug candidates, medical devices, and diagnostics, collectively, toward clinical trials, including a new class of drugs to treat epilepsy, new compounds for psychiatric treatment, therapeutics for Wilson’s disease, and improved treatment for macular degeneration
- Spun out 27 new companies have spun out of the Institute and received external investments exceeding $2 billion
And the Institute has:
- Acquired more than 50 new instruments and created new services to accelerate transdisciplinary research
- Developed new 21st century curricula and activities to support development of next gen scientists working across disciplinary boundaries to address the big questions in biomedical research
- Raised more than $50 million in new external funding to support these efforts
Attracting Early Stage Investment
Chemistry of Life Processes Institute partners with investment firms to introduce the translational research of some our most innovative faculty members to early stage biotech/pharma investors and industry leaders. These programs ensure continued financial support from the investment community that in turn drives future scientific exploration and innovation.
In May 2020, CLP hosted its second annual ‘Biotech Summit by the Lake,’ Investor Summit, supported by Oppeneheimer & Co. and BioCentury, Inc. Each year, the conference draws hundreds of investors, venture firms, and biopharma industry executives from across the US and beyond who want to learn more about Northwestern’s most translatable innovations and discoveries.
Following the 2019 conference, Oppenheimer’s biotech research analysts published an industry report highlighting CLP’s growing reputation as a biotech incubator and major hub for drug discovery and development in the Chicago-region.
CLP Institute’s Entrepreneur-in-Residence program, one of the first academic programs of its kind in the nation, helps move discoveries out of the lab and into clinics.
William Sargent, PhD, provides mentoring in the drug development process, from initiation to FDA marketing approval, to interested researchers across campus looking to explore commercialization. Bill has over 30 years in the pharmaceutical industry, preceded by 10 years as an independent researcher in academia. He is available on both the Chicago and Evanston campuses to consult with faculty, students and staff interested in developing potential therapies emerging from their translational research.
Learn About Academic Drug Development
Northwestern, Argonne, and partners to launch national resource to unlock the role of metals in human health
Evanston, IL - June 26, 2020: Chemistry of Life Processes Institute (CLP) at Northwestern, the Advanced Photon Source (APS) at Argonne National Laboratory, and several leading research universities, will join forces to launch a first-ever national hub for...
Northwestern University received $7 million this year from the National Institute of General Medical Sciences to continue to push the boundaries of precision proteomics through new technologies and approaches to heart disease, cancer, neurological diseases and...
On May 28, 2020, 300 investors, venture firms, pharma and biotech industry members and researchers, from across the US, Canada, China, UK and beyond tuned into the second annual Biotech by the Lake Investor Summit hosted by the Chemistry of Life Processes Institute...
Northwestern University researchers have, for the first time, determined the 3D atomic structure of a key complex in paramyxoviruses, a family of viruses that includes mumps, human parainfluenza and respiratory syncytial virus (RSV). This information could help others...
Companies Founded by CLP Faculty
Founder: Richard Silverman
Founders: Cheng Sun, Hao Zheng
Founder: Olga Volpert
Co-Founder: Jack Henkin
Founder: Thomas Meade
Founder: Thomas O’Halloran
Co-Founder: Chandler Robinson
Founder: Richard Silverman
Co-Founders: Dmitri Krainc
Founder: Jack Henkin
Co-Founders: Andrew Mazar, Olga Volpert
Northwestern Partners in Entrepreneurship
INVO catalyzes the translation of Northwestern innovations to benefit the public and promote economic growth. In order to maximize that outcome, Northwestern follows important principles when licensing university technology.
NewCures is a Northwestern initiative that focuses on accelerating biomedical research from early discovery stages to more advanced clinical stages for the benefit of the patients. The NewCures Fund aligns with existing resources to propel promising therapies towards commercialization.
Entrepreneurs-in-Residence (EIR) advise and assist faculty and students who are launching startups and commercializing IP. They are a resource for developing business concepts, making contacts with the market, connecting to investors, and forming organizational frameworks.
The CBC stimulates collaboration among researchers at Northwestern University, The University of Chicago, the University of Illinois at Chicago, and others to accelerate discovery that transforms biomedical research and improves the health of humankind.